However, the addition of SB-431542, a TGF-β receptor kinase inhibitor (TRKI), reversed the time-dependent increase in FERMT2 expression and inhibited the peritoneal metastasis capability of GC cells in vivo. Here, FERMT2 is linked to gastric cancer.